Damage to the cardiovascular system in COVID-19

Prof. O.M. Korzh

Kharkiv Medical Academy of Postgraduate Education

COVID-19 affects not only the respiratory system, but also the cardiovascular system. The damage to the cardiovascular system in COVID-19 is multifactorial and several mechanisms are involved, including direct invasion, inflammation, thrombosis, autoantibody synthesis, and oxygen imbalance. The inflammation causes the release of cytokines, especially interleukin-6, and damage to cardiomyocytes. The overproduction of cytokines leads to an abnormal inflammatory response called a cytokine storm, which is believed to be the culprit in cardiovascular events in COVID-19 patients. Treatment of COVID-19 patients with cardiovascular complications is mostly supportive. The role of pharmacological blocking of the renin-angiotensin-aldosterone system in patients with cardiovascular disease and COVID-19 infection requires further research as the relationship appears to be very complex. To date, professional cardiological societies do not recommend canceling ACE inhibitors or agiotensin II receptor antagonists for patients taking these drugs for other indications. Special care should be taken about the potential cardiovascular side effects of the various therapies used to treat viral infections. When using them, daily monitoring of the QT interval on the ECG is proposed.

Key Words: COVID-19, pandemic, myocardial injury, cardiovascular disease


Download.PDF (rus)

For citing:

1. Корж, А.Н. Поражение сердечно-сосудистой системы при COVID-19// Східноєвропейський журнал внутрішньої та сімейної медицини. – 2021. – №1. – С. 10-16. doi: 10.15407/internalmed2021.01.010

2. Korzh OM. [Damage to the cardiovascular system in COVID-19]. Shidnoevr. z. vnutr. simejnoi med. 2021;1:10-16. Russian. doi: 10.15407/internalmed2021.01.010


1. Hendren N, Drazner M, Bozkurt B, Cooper L. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020;141(23):1903-1914. http://dx.doi.org/10.1161/circulationaha.120.047349
2. Driggin E, Madhavan M, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown T, Der Nigoghossian C, Zidar D, Haythe J, Brodie D, Beckman J, Kirtane A, Stone G, Krumholz H, Parikh S. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. Journal of the American College of Cardiology. 2020;75(18):2352-2371. http://dx.doi.org/10.1016/j.jacc.2020.03.031
3. Geng Y, Wei Z, Qian H, Huang J, Lodato R, Castriotta R. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Cardiovascular Pathology. 2020;47:107228. http://dx.doi.org/10.1016/j.carpath.2020.107228
4. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, Yuan Q, Xiao X. The epidemiology and clinical information about COVID-19. European Journal of Clinical Microbiology & Infectious Diseases. 2020;39(6):1011-1019. http://dx.doi.org/10.1007/s10096-020-03874-z
5. Darmadi D, Ruslie R. Coronavirus Disease-2019 and Mental Health. Open Access Macedonian Journal of Medical Sciences. 2020;8(T1):268-271. http://dx.doi.org/10.3889/oamjms.2020.5304
6. Siregar G, Siregar G, Darmadi D, Ruslie R. Coronavirus Disease-19 and Liver Injury. Open Access Macedonian Journal of Medical Sciences. 2020;8(T1):154-157. http://dx.doi.org/10.3889/oamjms.2020.5028
7. Zhao M, Wang M, Zhang J, Ye J, Xu Y, Wang Z, Ye D, Liu J, Wan J. Advances in the relationship between coronavirus infection and cardiovascular diseases. Biomedicine & Pharmacotherapy. 2020;127:110230. http://dx.doi.org/10.1016/j.biopha.2020.110230
8. Srivastava K. Association between COVID-19 and cardiovascular disease. IJC Heart & Vasculature. 2020;29:100583. http://dx.doi.org/10.1016/j.ijcha.2020.100583
9. Guzik T, Mohiddin S, Dimarco A, Patel V, Savvatis K, Marelli-Berg F, Madhur M, Tomaszewski M, Maffia P, D’Acquisto F, Nicklin S, Marian A, Nosalski R, Murray E, Guzik B, Berry C, Touyz R, Kreutz R, Wang D, Bhella D, Sagliocco O, Crea F, Thomson E, McInnes I. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research. 2020;116(10):1666-1687. http://dx.doi.org/10.1093/cvr/cvaa106
10. Lazaridis C, Vlachogiannis N, Bakogiannis C, Spyridopoulos I, Stamatelopoulos K, Kanakakis I, Vassilikos V, Stellos K. Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. Hellenic Journal of Cardiology. 2020; 20:30093-102. http://dx.doi.org/10.1016/j.hjc.2020.05.004
11. Siregar G, Siregar G, Darmadi D. Gastrointestinal Aspects of COVID-19: A Review. Open Access Macedonian Journal of Medical Sciences. 2020;8(T1):52-54. http://dx.doi.org/10.3889/oamjms.2020.4891
12. Ruslie R, Darmadi D, Siregar G. Pediatric Immunization Practice During Coronavirus Disease-2019 Pandemic. Open Access Macedonian Journal of Medical Sciences. 2020;8(T1):258-260. http://dx.doi.org/10.3889/oamjms.2020.5125
13. Ruslie R, Darmadi D, Siregar G. Susceptibility of Coronavirus Disease-19 in Pediatric Population. Open Access Macedonian Journal of Medical Sciences. 2020;8(T1):363-365. http://dx.doi.org/10.3889/oamjms.2020.5240
14. Hafiane A. SARS-CoV-2 and the cardiovascular system. Clinica Chimica Acta. 2020;510:311-316. http://dx.doi.org/10.1016/j.cca.2020.07.019
15. de Vries A. SARS-CoV-2/COVID-19: a primer for cardiologists. Netherlands Heart Journal. 2020;28(7-8):366-383. http://dx.doi.org/10.1007/s12471-020-01475-1
16. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International Journal of Cardiology. 2020;309:70-77. http://dx.doi.org/10.1016/j.ijcard.2020.03.063
17. Nishiga M, Wang D, Han Y, Lewis D, Wu J. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology. 2020;17(9):543-558. http://dx.doi.org/10.1038/s41569-020-0413-9
18. Wu L, O’Kane A, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochemical Pharmacology. 2020;178:114114. http://dx.doi.org/10.1016/j.bcp.2020.114114
19. World Health Organization. Coronavirus disease (COVID-19) outbreak situation. Available from: covid19.who.int. Accessed: November 5, 2020.
20. Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, Chen Y, Han Y. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020;106(15):1132-1141. http://dx.doi.org/10.1136/heartjnl-2020-317056
21. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. European Heart Journal. 2020;42(2):206-206. http://dx.doi.org/10.1093/eurheartj/ehaa190

22. Hanley B, Lucas S, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. Journal of Clinical Pathology. 2020;73(5):239-242. http://dx.doi.org/10.1136/jclinpath-2020-206522
23. Liu K, Xu P, Lv W, Qiu X, Yao J, Gu J, Wei W. CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity. European Journal of Radiology. 2020;126:108941. http://dx.doi.org/10.1016/j.ejrad.2020.108941
24. Mehra M, Ruschitzka F. COVID-19 Illness and Heart Failure. JACC: Heart Failure. 2020;8(6):512-514. http://dx.doi.org/10.1016/j.jchf.2020.03.004
25. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. http://dx.doi.org/10.1001/jama.2020.1585
26. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China. JAMA Network Open. 2020;3(4):e205619. http://dx.doi.org/10.1001/jamanetworkopen.2020.5619
27. Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, Jing Z, Liu B, Chen J, Nie S, Zhu J, Li F, Ma C. CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic. Circulation. 2020;141(20):. http://dx.doi.org/10.1161/circulationaha.120.047011
28. Sanders J, Monogue M, Jodlowski T, Cutrell J. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020;:. http://dx.doi.org/10.1001/jama.2020.6019
29. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak. Journal of The Indian Academy of Echocardiography & Cardiovascular Imaging. 2020;4(1):137. http://dx.doi.org/10.4103/2543-1463.282193
30. Oren O, Kopecky S, Gluckman T. Coronavirus Disease 2019 (COVID-19): Epidemiology, Clinical Spectrum and Implications for the Cardiovascular Clinician. Available at: https://www.acc.org/latest-in-cardiology/ articles/2020/04/06/11/08/covid-19-epidemiology-clinicalspectrum-and-implications-for-the-cv-clinician [Accessed 10 April 2020].